CANbridge doses first patient in phase 2 EMBARK study of CAN108 in BA
CANbridge Pharmaceuticals has dosed the first patient in the phase 2 EMBARK study of CAN108 (maralixibat) in biliary atresia (BA) in China. The clinical trial in China is part of the larger EMBARK clinical trial in biliary atresia, which is being carried out at various sites in North America, Asia, and Europe. The multi-center randomized […]